Expanding the genetic spectrum of hereditary motor sensory neuropathies in Pakistan.
CMT
Clinical heterogeneity
Genetic variants
HMSN
Pakistan
Whole exome sequencing
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
16 Oct 2024
16 Oct 2024
Historique:
received:
13
12
2023
accepted:
25
09
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
Hereditary motor and sensory neuropathy (HMSN) refers to a group of inherited progressive peripheral neuropathies characterized by reduced nerve conduction velocity with chronic segmental demyelination and/or axonal degeneration. HMSN is highly clinically and genetically heterogeneous with multiple inheritance patterns and phenotypic overlap with other inherited neuropathies and neurodegenerative diseases. Due to this high complexity and genetic heterogeneity, this study aimed to elucidate the genetic causes of HMSN in Pakistani families using Whole Exome Sequencing (WES) for variant identification and Sanger sequencing for validation and segregation analysis, facilitating accurate clinical diagnosis. Families from Khyber Pakhtunkhwa with at least two members showing HMSN symptoms, who had not previously undergone genetic analysis, were included. Referrals for genetic investigations were based on clinical features suggestive of HMSN by local neurologists. WES was performed on affected individuals from each family, with Sanger sequencing used to validate and analyze the segregation of identified variants among family members. Clinical data including age of onset were assessed for variability among affected individuals, and the success rate of genetic diagnosis was compared with existing literature using proportional differences and Cohen's h. WES identified homozygous pathogenic variants in GDAP1 (c.310 + 4 A > G, p.?), SETX (c.5948_5949del, p.(Asn1984Profs*30), IGHMBP2 (c.1591 C > A, p.(Pro531Thr) and NARS1 (c.1633 C > T, p.(Arg545Cys) as causative for HMSN in five out of nine families, consistent with an autosomal recessive inheritance pattern. Additionally, in families with HMSN, a SETX variant was found to cause cerebellar ataxia, while a NARS1 variant was linked to intellectual disability. Based on American College of Medical Genetics and Genomics criteria, the GDAP1 variant is classified as a variant of uncertain significance, while variants in SETX and IGHMBP2 are classified as pathogenic, and the NARS1 variant is classified as likely pathogenic. The age of onset ranged from 1 to 15 years (Mean = 5.13, SD = 3.61), and a genetic diagnosis was achieved in 55.56% of families with HMSN, with small effect sizes compared to previous studies. This study expands the molecular genetic spectrum of HMSN and HMSN plus type neuropathies in Pakistan and facilitates accurate diagnosis, genetic counseling, and clinical management for affected families.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary motor and sensory neuropathy (HMSN) refers to a group of inherited progressive peripheral neuropathies characterized by reduced nerve conduction velocity with chronic segmental demyelination and/or axonal degeneration. HMSN is highly clinically and genetically heterogeneous with multiple inheritance patterns and phenotypic overlap with other inherited neuropathies and neurodegenerative diseases. Due to this high complexity and genetic heterogeneity, this study aimed to elucidate the genetic causes of HMSN in Pakistani families using Whole Exome Sequencing (WES) for variant identification and Sanger sequencing for validation and segregation analysis, facilitating accurate clinical diagnosis.
METHODS
METHODS
Families from Khyber Pakhtunkhwa with at least two members showing HMSN symptoms, who had not previously undergone genetic analysis, were included. Referrals for genetic investigations were based on clinical features suggestive of HMSN by local neurologists. WES was performed on affected individuals from each family, with Sanger sequencing used to validate and analyze the segregation of identified variants among family members. Clinical data including age of onset were assessed for variability among affected individuals, and the success rate of genetic diagnosis was compared with existing literature using proportional differences and Cohen's h.
RESULTS
RESULTS
WES identified homozygous pathogenic variants in GDAP1 (c.310 + 4 A > G, p.?), SETX (c.5948_5949del, p.(Asn1984Profs*30), IGHMBP2 (c.1591 C > A, p.(Pro531Thr) and NARS1 (c.1633 C > T, p.(Arg545Cys) as causative for HMSN in five out of nine families, consistent with an autosomal recessive inheritance pattern. Additionally, in families with HMSN, a SETX variant was found to cause cerebellar ataxia, while a NARS1 variant was linked to intellectual disability. Based on American College of Medical Genetics and Genomics criteria, the GDAP1 variant is classified as a variant of uncertain significance, while variants in SETX and IGHMBP2 are classified as pathogenic, and the NARS1 variant is classified as likely pathogenic. The age of onset ranged from 1 to 15 years (Mean = 5.13, SD = 3.61), and a genetic diagnosis was achieved in 55.56% of families with HMSN, with small effect sizes compared to previous studies.
CONCLUSIONS
CONCLUSIONS
This study expands the molecular genetic spectrum of HMSN and HMSN plus type neuropathies in Pakistan and facilitates accurate diagnosis, genetic counseling, and clinical management for affected families.
Identifiants
pubmed: 39415096
doi: 10.1186/s12883-024-03882-y
pii: 10.1186/s12883-024-03882-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
394Subventions
Organisme : Higher Education Commision, Pakistan
ID : 1-8/HEC/HRD/2023/12794/PIN: IRSIP 52 BMS 06
Organisme : Kohat University of Science and Technology, Kohat, Pakistan
ID : ORIC grant # No. KUST/ORIC/21/2268)
Informations de copyright
© 2024. The Author(s).
Références
Mathis S, Goizet C, Tazir M, Magdelaine C, Lia AS, Magy L, et al. Charcot–Marie–Tooth diseases: an update and some new proposals for the classification. J Med Genet. 2015;52(10):681–90. https://doi.org/10.1136/jmedgenet-2015-103272 .
Pipis M, Rossor AM, Laura M, Reilly MM. Next-generation sequencing in Charcot–Marie–Tooth disease: opportunities and challenges. Nat Rev Neurol. 2019;15(11):644–56. https://doi.org/10.1038/s41582-019-0254-5 .
doi: 10.1038/s41582-019-0254-5
pubmed: 31582811
Laurá M, Pipis M, Rossor AM, Reilly MM. Charcot–Marie–tooth disease and related disorders: an evolving landscape. Curr Opin Neurol. 2019;32(5):641–50. https://doi.org/10.1097/WCO.0000000000000735 .
doi: 10.1097/WCO.0000000000000735
pubmed: 31343428
Shchagina O, Orlova M, Murtazina A, Filatova A, Skoblov M, Dadali E. Evaluation of pathogenicity and causativity of variants in the MPZ and SH3TC2 genes in a family case of hereditary peripheral neuropathy. Int J Mol Sci. 2023;24(12):9786. https://doi.org/10.3390/ijms24129786 .
doi: 10.3390/ijms24129786
pubmed: 37372933
pmcid: 10298462
Cordeiro JLC, Marques W, Hallak JEC, Osório FL. Charcot-Marie-Tooth Disease, Psychiatric indicators and Quality of Life: a systematic review. ASN Neuro. 2014;6(3):185–92. https://doi.org/10.1042/an20130048 .
Yasha T, Sharma S, Gayathri N, Nandeesh N. Hereditary neuropathies: genetics and utility of nerve biopsy. Indian J Pathol Microbiol. 2022;65(Supplement):S318–28. https://doi.org/10.4103/ijpm.ijpm_146_22 .
Visser HJ, Wolfe J, Kouri R, Aviles R. Neurologic conditions associated with cavus foot deformity. Clin Podiatr Med Surg. 2021;38(3):323–42. https://doi.org/10.1016/j.cpm.2021.03.001 .
doi: 10.1016/j.cpm.2021.03.001
pubmed: 34053647
Martin PB, Hicks AN, Holbrook SE, Cox GA. Overlapping spectrums: the clinicogenetic commonalities between Charcot-Marie-Tooth and other neurodegenerative diseases. Brain Res. 2020;1727:146532. https://doi.org/10.1016/j.brainres.2019.146532 .
doi: 10.1016/j.brainres.2019.146532
pubmed: 31678418
Lupo V, Sancho P, Espinós C. Hereditary motor neuropathies and overlapping conditions. Factors affecting Neurodevelopment. Elsevier; 2021. pp. 3–14.
Masingue M, Fernández-Eulate G, Debs R, Tard C, Labeyrie C, Leonard-Louis S, et al. Strategy for genetic analysis in hereditary neuropathy. Rev Neurol. 2023;179(1–2):10–29. https://doi.org/10.1016/j.neurol.2022.11.007 .
Manzoor U, Ali A, Ali SL, Abdelkarem O, Kanwal S, Alotaibi SS, et al. Mutational screening of GDAP1 in dysphonia associated with Charcot-Marie-Tooth disease: clinical insights and phenotypic effects. J Genet Eng Biotechnol. 2023;21(1):119. https://doi.org/10.1186/s43141-023-00568-9 .
Ma M, Li Y, Dai S, Chu M, Sun L, Liu L, et al. A meta-analysis on the prevalence of Charcot–Marie–Tooth disease and related inherited peripheral neuropathies. J Neurol. 2023;270(5):2468–82. https://doi.org/10.1007/s00415-023-11559-8 .
Finsterer J, Löscher WN, Wanschitz J, Iglseder S. Orphan peripheral neuropathies. J Neuromuscul Dis. 2021;8(1):1–23. https://doi.org/10.3233/JND-200518 .
doi: 10.3233/JND-200518
pubmed: 32986679
pmcid: 7902989
Dubourg O, Azzedine H, Verny C, Durosier G, Birouk N, Gouider R, et al. Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromol Med. 2006;8(1–2):75–85. https://doi.org/10.1385/nmm:8:1-2:75 .
Tazir M, Bellatache M, Nouioua S, Vallat JM. Autosomal recessive Charcot-Marie‐Tooth disease: from genes to phenotypes. J Peripheral Nerv Syst. 2013;18(2):113–29. https://doi.org/10.1111/jns5.12026 .
doi: 10.1111/jns5.12026
Schabhüttl M, Wieland T, Senderek J, Baets J, Timmerman V, De Jonghe P, et al. Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges. J Neurol. 2014;261:970–82. https://doi.org/10.1007/s00415-014-7289-8 .
Baets J, Deconinck T, De Vriendt E, Zimoń M, Yperzeele L, Van Hoorenbeeck K, et al. Genetic spectrum of hereditary neuropathies with onset in the first year of life. Brain. 2011;134(Pt 9):2664–76. https://doi.org/10.1093/brain/awr184 .
Geroldi A, Ponti C, Mammi A, Patrone S, Gotta F, Trevisan L, et al. Early onset inherited Peripheral neuropathies: the experience of a Specialized Referral Center for genetic diagnosis achievement. Pediatr Neurol. 2024;154:4–8. https://doi.org/10.1016/j.pediatrneurol.2024.02.002 .
Figueiredo FB, Tomaselli PJ, Hallak J, Mattiello-Sverzut AC, Covaleski APPM, Sobreira CFR, et al. Genetic diversity in hereditary axonal neuropathy: analyzing 53 Brazilian children. J Peripheral Nerv Syst. 2024;29(1):97–106. https://doi.org/10.1111/jns.12617 .
Kozjak-Pavlovic V, Prell F, Thiede B, Götz M, Wosiek D, Ott C, et al. C1orf163/RESA1 is a novel mitochondrial intermembrane space protein connected to respiratory chain assembly. J Mol Biol. 2014;426(4):908–20. https://doi.org/10.1016/j.jmb.2013.12.001 .
Bacquet J, Stojkovic T, Boyer A, Martini N, Audic F, Chabrol B, et al. Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. BMJ Open. 2018;8:e021632. https://doi.org/10.1136/bmjopen-2018-021632 .
Benquey T, Pion E, Cossée M, Krahn M, Stojkovic T, Perrin A, et al. A National French Consensus on Gene List for the diagnosis of Charcot–Marie–Tooth disease and related disorders using next-generation sequencing. Genes (Basel). 2022;13(2):318. https://doi.org/10.3390/genes13020318 .
Hsu YH, Lin KP, Guo YC, Tsai YS, Liao YC, Lee YC. Mutation spectrum of Charcot-Marie‐Tooth disease among the Han Chinese in Taiwan. Ann Clin Transl Neurol. 2019;6(6):1090–101. https://doi.org/10.1002/acn3.50797 .
doi: 10.1002/acn3.50797
pubmed: 31211173
pmcid: 6562034
Azzedine H, Salih MA. SH3TC2-Related Hereditary Motor and Sensory Neuropathy. 2008 Mar 31 [Updated 2021 Mar 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;1993-2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1340/ .
Cortese A, Zhu Y, Rebelo AP, Negri S, Courel S, Abreu L, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;52(5):473–481. https://doi.org/10.1038/s41588-020-0615-4 .
Grunseich C, Sarkar N, Lu J, Owen M, Schindler A, Calabresi PA, et al. Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases. J Neurol Neurosurg Psychiatry. 2021;92(11):1186–1196. https://doi.org/10.1136/jnnp-2020-325437 .
Parmar JM, Laing NG, Kennerson ML, Ravenscroft G. Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards. J Neurol Neurosurg Psychiatry. 2024. https://doi.org/10.1136/jnnp-2024-333436 .
doi: 10.1136/jnnp-2024-333436
pubmed: 38744462
Pedurupillay CRJ, Amundsen SS, Barøy T, Rasmussen M, Blomhoff A, Stadheim BF, et al. Clinical and molecular characteristics in three families with biallelic mutations in IGHMBP2. Neuromuscul Disord. 2016;26(9):570–5. https://doi.org/10.1016/j.nmd.2016.06.457 .
Wright GC, Brown R, Grayton H, Livingston JH, Park SM, Parker AP, et al. Clinical and radiological characterization of novel FIG4-related combined system disease with neuropathy. Clin Genet. 2020;98(2):147–154. https://doi.org/10.1111/cge.13771 .
Houlden H, Laura M, Ginsberg L, Jungbluth H, Robb SA, Blake J, et al. The phenotype of Charcot–Marie–Tooth disease type 4 C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. Neuromuscul Disord. 2009;19(4):264–9. https://doi.org/10.1016/j.nmd.2009.01.006 .
Zambon AA, Sora MGN, Cantarella G, Cerri F, Quattrini A, Comi G, et al. Vocal cord paralysis in Charcot–Marie–Tooth type 4b1 disease associated with a novel mutation in the myotubularin-related protein 2 gene: a case report and review of the literature. Neuromuscul Disord. 2017;27(5):487–91. https://doi.org/10.1016/j.nmd.2017.01.006 .
Kanwal S, Perveen S, Arshad HM. Role of alpha-methylacyl-CoA racemase gene in pathogenecity of CMT patients. J Pak Med Assoc. 2018;68(7):1039–42.
pubmed: 30317298
Kanwal S, Choi YJ, Lim SO, Choi HJ, Park JH, Nuzhat R, et al. Novel homozygous mutations in Pakistani families with Charcot–Marie–Tooth disease. BMC Med Genomics. 2021;14(1):174. https://doi.org/10.1186/s12920-021-01019-5 .
Asif M, Chiou CC, Hussain MF, Hussain M, Sajid Z, Gulsher M, et al. Homozygous mutations in GDAP1 and MFN2 genes resulted in autosomal recessive forms of Charcot-Marie-Tooth disease in consanguineous Pakistani families. DNA Cell Biol. 2023;42(11):697–708. https://doi.org/10.1089/dna.2023.0169 .
Zaman Q, Khan MA, Sahar K, Rehman G, Khan H, Rehman M, et al. Novel variants in MPV17, PRX, GJB1, and SACS cause Charcot-Marie-Tooth and spastic ataxia of Charlevoix-Saguenay type diseases. Genes (Basel). 2023;14(2):328. https://doi.org/10.3390/genes14020328 .
Shafique A, Sultan T, Alzahrani F, Seo GH, Alkuraya FS, Naz S. Genomic analysis of multiplex consanguineous families reveals causes of neurodevelopmental disorders with epilepsy. Gene. 2023;879:147599. https://doi.org/10.1016/j.gene.2023.147599 .
doi: 10.1016/j.gene.2023.147599
pubmed: 37393059
Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, et al. Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. Hum Mutat. 2018;39(11):1593–613. https://doi.org/10.1002/humu.23630 .
Karbassi I, Maston GA, Love A, DiVincenzo C, Braastad CD, Elzinga CD, et al. A standardized DNA variant scoring system for pathogenicity assessments in Mendelian disorders. Hum Mutat. 2016;37(1):127–34. https://doi.org/10.1002/humu.22918 .
Gonzaga-Jauregui C, Harel T, Gambin T, Kousi M, Griffin LB, Francescatto L, et al. Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy. Cell Rep. 2015;12(7):1169–83. https://doi.org/10.1016/j.celrep.2015.07.023 .
Candayan A, Çakar A, Yunisova G, Özdağ Acarlı AN, Atkinson D, Topaloğlu P, et al. Genetic survey of autosomal recessive peripheral neuropathy cases unravels high genetic heterogeneity in a Turkish cohort. Neurol Genet. 2021;7(5):e621. https://doi.org/10.1212/NXG.0000000000000621 .
Cottenie E, Kochanski A, Jordanova A, Bansagi B, Zimon M, Horga A, et al. Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2. Am J Hum Genet. 2014;95(5):590–601. https://doi.org/10.1016/j.ajhg.2014.10.002 .
Manole A, Efthymiou S, O’Connor E, Mendes MI, Jennings M, Maroofian R, et al. De Novo and bi-allelic pathogenic variants in NARS1 cause neurodevelopmental delay due to toxic gain-of-function and partial loss-of-function effects. Am J Hum Genet. 2020;107(2):311–24. https://doi.org/10.1016/j.ajhg.2020.06.016 .
Koch L. Exploring human genomic diversity with gnomAD. Nat Rev Genet. 2020;21(8):448. https://doi.org/10.1038/s41576-020-0255-7 .
doi: 10.1038/s41576-020-0255-7
pubmed: 32488197
Riaz M, Tiller J, Ajmal M, Azam M, Qamar R, Lacaze P. Implementation of public health genomics in Pakistan. Eur J Hum Genet. 2019;27(10):1485–92. https://doi.org/10.1038/s41431-019-0428-z .
doi: 10.1038/s41431-019-0428-z
pubmed: 31101884
pmcid: 6777461
Rudnik-Schöneborn S, Tölle D, Senderek J, Eggermann K, Elbracht M, Kornak U, et al. Diagnostic algorithms in Charcot–Marie–Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients. Clin Genet. 2016;89(1):34–43. https://doi.org/10.1111/cge.12594 .
Crimella C, Tonelli A, Airoldi G, Baschirotto C, d’Angelo MG, Bonato S, et al. The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K. J Med Genet. 2010;47(10):712–6. https://doi.org/10.1136/jmg.2010.077909 .
Sivera R, Frasquet M, Lupo V, García-Sobrino T, Blanco-Arias P, Pardo J, et al. Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain. Sci Rep. 2017;7(1):6677. https://doi.org/10.1038/s41598-017-06894-6 .
Kabzińska D, Kochański A, Drac H, Ryniewicz B, Rowińska-Marcińska K, Hausmanowa-Petrusewicz I. Autosomal recessive axonal form of Charcot-Marie-Tooth disease caused by compound heterozygous 3′-splice site and Ser130Cys mutation in the GDAP1 gene. Neuropediatrics. 2005;36(3):206–9. https://doi.org/10.1055/s-2005-865606 .
Figueiredo FB, Silva WA Jr., Giuliatti S, Tomaselli PJ, Lourenço CM, Gouvêa SP, et al. GDAP1 mutations are frequent among Brazilian patients with autosomal recessive axonal Charcot-Marie-Tooth disease. Neuromuscul Disord. 2021;31(6):505–11. https://doi.org/10.1016/j.nmd.2021.03.005 .
Khani M, Taheri H, Shamshiri H, Moazzeni H, Hardy J, Bras JT, et al. Deep geno- and phenotyping in two consanguineous families with CMT2 reveals HADHA as an unusual disease-causing gene and an intronic variant in GDAP1 as an unusual mutation. J Neurol. 2021;268(2):640–50. https://doi.org/10.1007/s00415-020-10171-4 .
Correia Rodrigues C, Oliveira Santos M. An axonal Charcot-Marie-Tooth disease associated with a homozygous GDAP1 gene mutation in two siblings from Bangladesh: a less severe phenotype. Acta Neurol Belg. 2022;122(3):841–2. https://doi.org/10.1007/s13760-022-01884-6 .
Cassereau J, Chevrollier A, Gueguen N, Desquiret V, Verny C, Nicolas G, et al. Mitochondrial dysfunction and pathophysiology of Charcot–Marie–Tooth disease involving GDAP1 mutations. Exp Neurol. 2011;227(1):31–41. https://doi.org/10.1016/j.expneurol.2010.09.006 .
Moroni I, Morbin M, Milani M, Ciano C, Bugiani M, Pagliano E, et al. Novel mutations in the GDAP1 gene in patients affected with early-onset axonal Charcot-Marie-Tooth type 4A. Neuromuscul Disord. 2009;19(7):476–80. https://doi.org/10.1016/j.nmd.2009.04.014 .
Azzedine H, Ruberg M, Ente D, Gilardeau C, Périé S, Wechsler B, et al. Variability of disease progression in a family with autosomal recessive CMT associated with a S194X and new R310Q mutation in the GDAP1 gene. Neuromuscul Disord. 2003;13(40):341–346. https://doi.org/10.1016/S0960-8966(02)00281-X .
Baxter RV, Ben Othmane K, Rochelle JM, Stajich JE, Hulette C, Dew-Knight S, et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet. 2002;30(1):21–2. https://doi.org/10.1038/ng796 .
Nelis E, Erdem S, Van den Bergh P, Belpaire–Dethiou M-C, Ceuterick C, Van Gerwen V, et al. Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy. Neurology. 2002;59(12):1865–72. https://doi.org/10.1212/01.wnl.0000036272.36047.54 .
Niemann A, Ruegg M, La Padula V, Schenone A, Suter U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol. 2005;170(7):1067–78. https://doi.org/10.1083/jcb.200507087 .
Chung KW, Kim SM, Sunwoo IN, Cho SY, Hwang SJ, Kim J, et al. A novelGDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease. J Hum Genet. 2008;53(4):360–4. https://doi.org/10.1007/s10038-008-0249-3 .
Pedrola L, Espert A, Valdés-Sánchez T, Sánchez‐Piris M, Sirkowski EE, Scherer SS, et al. Cell expression of GDAP1 in the nervous system and pathogenesis of Charcot‐Marie‐Tooth type 4A disease. J Cell Mol Med. 2008;12(2):679–89. https://doi.org/10.1111/j.1582-4934.2007.00158.x .
Estela A, Pla-Martín D, Sánchez-Piris M, Sesaki H, Palau F. Charcot-Marie-Tooth-related gene GDAP1 complements cell cycle delay at G2/M phase in Saccharomyces cerevisiae fis1 gene-defective cells. J Biol Chem. 2011;286(42):36777–86. https://doi.org/10.1074/jbc.M111.260042 .
Chen CX, Li JQ, Dong HL, Liu GL, Bai G, Wu ZY. Identification and functional characterization of novel GDAP1 variants in Chinese patients with Charcot–Marie–Tooth disease. Ann Clin Transl Neurol. 2020;7(12):2381–92. https://doi.org/10.1002/acn3.51233 .
Huber N, Bieniossek C, Wagner KM, Elsässer H-P, Suter U, Berger I, et al. Glutathione-conjugating and membrane-remodeling activity of GDAP1 relies on amphipathic C-terminal domain. Sci Rep. 2016;6:36930. https://doi.org/10.1038/srep36930 .
Tariq H, Imran R, Naz S. A novel homozygous variant of SETX causes ataxia with oculomotor apraxia type 2. J Clin Neurol. 2018;14(4):498–504. https://doi.org/10.3988/jcn.2018.14.4.498 .
Martínez-Rubio D, Hinarejos I, Argente-Escrig H, Marco-Marín C, Lozano MA, Gorría-Redondo N, et al. Genetic heterogeneity underlying phenotypes with early-onset cerebellar atrophy. Int J Mol Sci. 2023;24(22):16400. https://doi.org/10.3390/ijms242216400 .
Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009;132(10):2688–98. https://doi.org/10.1093/brain/awp211 .
Moreira MC, Klur S, Watanabe M, Németh AH, Le Ber I, Moniz JC, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet. 2004;36(3):225–7. https://doi.org/10.1038/ng1303 .
Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74(6):1128–35. https://doi.org/10.1086/421054 .
Duquette A, Roddier K, McNabb-Baltar J, Gosselin I, St‐Denis A, Dicaire MJ, et al. Mutations in senataxin responsible for Quebec cluster of ataxia with neuropathy. Ann Neurol. 2005;57(3):408–14. https://doi.org/10.1002/ana.20408 .
Groh M, Albulescu LO, Cristini A, Gromak N. Senataxin: genome guardian at the interface of transcription and neurodegeneration. J Mol Biol. 2017;429(21):3181-3195. https://doi.org/10.1016/j.jmb.2016.10.021 .
Nanetti L, Cavalieri S, Pensato V, Erbetta A, Pareyson D, Panzeri M, et al. SETX mutations are a frequent genetic cause of juvenile and adult onset cerebellar ataxia with neuropathy and elevated serum alpha-fetoprotein. Orphanet J Rare Dis. 2013;8;123. https://doi.org/10.1186/1750-1172-8-123 .
Gatti V, De Domenico S, Melino G, Peschiaroli A. Senataxin and R-loops homeostasis: multifaced implications in carcinogenesis. Cell Death Discov. 2023;9(1):145. https://doi.org/10.1038/s41420-023-01441-x .
Higuchi Y, Takashima H. Clinical genetics of Charcot–Marie–Tooth disease. J Hum Genet. 2023;68(3):199–214. https://doi.org/10.1038/s10038-022-01031-2 .
de Planell-Saguer M, Schroeder DG, Rodicio MC, Cox GA, Mourelatos Z. Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery. Hum Mol Genet. 2009;18(12):2115–26. https://doi.org/10.1093/hmg/ddp134 .
Pitt M, Houlden H, Jacobs J, Mok Q, Harding B, Reilly M, et al. Severe infantile neuropathy with diaphragmatic weakness and its relationship to SMARD1. Brain. 2003;126(12):2682–92. https://doi.org/10.1093/brain/awg278 .
Schottmann G, Jungbluth H, Schara U, Knierim E, Gonzalez SM, Gill E, et al. Recessive truncating IGHMBP2 mutations presenting as axonal sensorimotor neuropathy. Neurology. 2015;84(5):523–31. https://doi.org/10.1212/WNL.0000000000001220 .
Rzepnikowska W, Kochański A. Models for IGHMBP2-associated diseases: an overview and a roadmap for the future. Neuromuscul Disord. 2021;31(12):1266–78. https://doi.org/10.1016/j.nmd.2021.08.001 .
Lim SC, Bowler MW, Lai TF, Song H. The Ighmbp2 helicase structure reveals the molecular basis for disease-causing mutations in DMSA1. Nucleic Acids Res. 2012;40(21):11009–22; https://doi.org/10.1093/nar/gks792 .
Kanaan J, Raj S, Decourty L, Saveanu C, Croquette V, Le Hir H. UPF1-like helicase grip on nucleic acids dictates processivity. Nat Commun. 2018;9:3752. https://doi.org/10.1038/s41467-018-06313-y .
Jaudzems K, Jia X, Yagi H, Zhulenkovs D, Graham B, Otting G, Liepinsh E. Structural basis for 5′-End-specific recognition of single-stranded DNA by the R3H domain from human Sµbp-2. J Mol Biol. 2012;424(1-2):42–53. https://doi.org/10.1016/j.jmb.2012.09.010 .
Eckart M, Guenther UP, Idkowiak J, Varon R, Grolle B, Boffi P, et al. The natural course of infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Pediatrics. 2012;129(1):e148–56. https://doi.org/10.1542/peds.2011-0544 .
Guenther UP, Handoko L, Laggerbauer B, Jablonka S, Chari A, Alzheimer M, et al. IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1). Hum Mol Genet. 2009;18(7):1288–300. https://doi.org/10.1093/hmg/ddp028 .
Liu L, Li X, Hu Z, Mao X, Zi X, Xia K, et al. IGHMBP2-related clinical and genetic features in a cohort of Chinese Charcot-Marie-Tooth disease type 2 patients. Neuromuscul Disord. 2017;27(2):193–9. https://doi.org/10.1016/j.nmd.2016.11.008 .
Ratanayotha A, Matsuda M, Kimura Y, Takenaga F, Mizuno T, Hossain MI, et al. Voltage-sensing phosphatase (vsp) regulates endocytosis-dependent nutrient absorption in chordate enterocytes. Commun Biol. 2022;5(1):948. https://doi.org/10.1038/s42003-022-03916-6 .
Bird TD, Charcot-Marie-Tooth Hereditary Neuropathy Overview. 1998 Sep 28 [updated 2024 Aug 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews